Filing Details

Accession Number:
0001209191-21-027329
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-19 17:17:39
Reporting Period:
2021-04-15
Accepted Time:
2021-04-19 17:17:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1515673 Ultragenyx Pharmaceutical Inc. RARE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1326969 L Camille Bedrosian C/O Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato CA 94949
Evp And Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-15 5,000 $55.00 44,139 No 4 M Direct
Common Stock Disposition 2021-04-15 5,000 $109.09 39,139 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2021-04-15 5,000 $0.00 5,000 $55.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
58,000 2028-01-30 No 4 M Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.35 to $110.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
  4. The option vested with respect to 1/4th of the shares on January 30, 2019 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant date.